Allogeneic Cell Therapy Market Revenue to Cross US$ 2.7 billion by 2035 | Roots Analysis

Published: August 2023


According to a recently published report by Roots Analysis, allogeneic cell therapies have emerged as a promising and rapidly advancing modality, owing to their various benefits, including off-the-shelf availability, reduced treatment time, broader applicability, relatively lower cost and easy scalability

Allogeneic Cell Therapy Industry Overview

The global allogeneic cell therapy market is anticipated to grow at a CAGR of 14.5% from 2023-2035, reaching USD 2.7 billion by 2035.

Several industry players and academic / research institutes across the world are investigating different types of allogeneic cell therapies (such as stem cell therapies, T-cell therapies, natural killer cell therapies and dendritic cell therapies) to treat a multitude of indications. Further, advancements in gene editing technologies, cell manufacturing techniques and genetic engineering tools have significantly contributed to the progress in this domain, by enhancing their therapeutic potential and reducing the risk of immune rejection.

To order this 220+ page report, which features 145+ figures and 135+ tables, please visit https://www.rootsanalysis.com/reports/allogeneic-cell-therapy-market.html

Market Drivers

Several factors are propelling the growth of the allogeneic cell therapies market. The growing incidence of chronic diseases (such as cancer and autoimmune disorders) demands effective and targeted treatments, such as allogeneic cell therapies; as a result, there has been an increase in their research and development, clinical studies and manufacturing. Since the cells are used from healthy donors, the quality of these therapies is high; further, these therapies are suitable for patients in which autologous therapies are not possible (such as patients exposed to chemotherapeutic agents). Another market driver for allogeneic therapies is the flexibility offered by them - the same donor or a different one can be approached for developing subsequent / additional therapeutics. Notably, allogeneic therapies yield numerous doses from a single batch, catering to multiple patients and reducing costs (when compared to patient-specific autologous therapies).

Market Restraints

One of the primary restraints associated with this industry is the need for robust technologies and a meticulously controlled manufacturing process; this is important for generating a substantial quantity of cells that are not only safe but also efficacious. Another critical challenge with allogeneic cell therapies is the recognition of donor cells as foreign entities by the recipient's immune system, thereby leading to the risk of rejection and graft failure. Further, there are concerns related to Human leukocyte antigen (HLA) mismatch, where transplanted cells may inadvertently target healthy cells in the patient's body, leading to potentially life-threatening condition.

Growth Factors

Despite the challenges, various factors promote the growth of allogeneic cell therapies market. Advances in biotechnology and immunology have paved the way for innovative approaches in harnessing allogeneic cells. Additionally, the increasing investments from both public and private sectors has accelerated the discovery of novel allogeneic cell therapies. Moreover, collaborative efforts among pharmaceutical companies, academic institutions, and research organizations to address unmet medical needs globally has led the market to experience robust growth.

Allogeneic Cell Therapy Market Segments

Based on Type of Cell Therapy, the market is segmented into Stem Cell Therapies, Virus-Specific T-cell Therapies and Regulatory T-cell Therapies

  • The stem cell therapy segment led the allogeneic cell therapy market, capturing the largest revenue share of close to 90% in 2023.
  • Moreover, regulatory T-cell therapies segment is anticipated to show highest market growth potential at a CAGR of 23% during the forecast period.

Based on Source of Cell, the market is segmented into Bone Marrow / Matrix, Peripheral Blood, Placenta, Adipose Tissue, Umbilical Cord, Placenta and Others

  • The bone marrow / matrix segment led the allogeneic cell therapy market, capturing the largest revenue share of close to 70% in 2023.
  • In fact, the adipose tissue-derived therapies segment is anticipated to show highest market growth potential at a CAGR of 25% during the forecast period.

Based on Target Indication, the market is segmented into Infectious Disease, Chronic Heart Failure, Crohn’s Disease, Ischemic Stroke, Hematological Cancer, Bone Disorder, Critical Limb Ischemia, Graft versus Host Disease, Duchenne Muscular Dystrophy, Epidermolysis Bullosa, Diabetic Foot Ulcer and Others

  • Chronic Heart Failure segment led the allogeneic cell therapy market, capturing the largest revenue share of 31% in 2023.
  • In fact, epidermolysis bullosa segment is anticipated to show highest market growth potential at a CAGR of 27% during the forecast period.

Based on Therapeutic Area, the market is segmented into Post-Transplant Infections, Cardiovascular Disorders, Autoimmune / Inflammatory Disorders, Cerebrovascular Disorders, Musculoskeletal Disorders, Oncological Disorders, Neurological Disorders, Genetic Disorders and Others

  • Cardiovascular Disorders segment led the allogeneic cell therapy market, capturing the largest revenue share of 31% in 2023.
  • In fact, autoimmune / inflammatory disorders segment is anticipated to show highest market growth potential at a CAGR of 25% during the forecast period.

Based on Regional Insights, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World

  • North America dominated the allogeneic cell therapy market and accounted for the largest revenue share of around 75% in 2023.
  • In Europe, the allogeneic cell therapy market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Covered

Key companies (based on the number of allogeneic cell therapies being developed; arranged in alphabetical order) covered in the report include:

  • Artiva Biotherapeutics
  • Allogene Therapeutics
  • Celularity
  • Cellenkos
  • Cell2Cure
  • CHABiotech
  • CRISPR Therapeutics
  • Fate Therapeutics
  • Fundamenta Therapeutics
  • GC Cell
  • Mesoblast
  • Nanjing Bioheng Biotech
  • Stemedica Cell Technologies

You Can Download Free Sample PDF Copy of This Report At: 
https://www.rootsanalysis.com/reports/allogeneic-cell-therapy-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry